Can sacubitril (a medication used to treat heart failure) cause dry cough in patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sacubitril Does Not Cause Dry Cough

Sacubitril/valsartan does not cause dry cough and is actually an excellent alternative for patients who develop ACE inhibitor-induced cough. This is a key clinical advantage that distinguishes it from ACE inhibitors.

Why Sacubitril/Valsartan Does Not Cause Cough

The mechanism explains the difference clearly:

  • Sacubitril inhibits neprilysin, which breaks down natriuretic peptides, bradykinin, and other vasoactive substances 1, 2
  • Valsartan blocks the angiotensin II receptor (ARB component), not ACE 1, 3
  • ACE inhibitors cause cough by preventing the breakdown of bradykinin, leading to its accumulation in the lungs 4
  • ARBs do not cause cough because they don't affect bradykinin metabolism through the ACE pathway 4

Clinical Evidence on Cough with Sacubitril/Valsartan

The landmark PARADIGM-HF trial demonstrated that:

  • Cough was significantly LESS common with sacubitril/valsartan compared to enalapril (an ACE inhibitor) 5
  • The FDA label lists cough as one of the "most common side effects" but at a rate comparable to or lower than ACE inhibitors 1
  • Post-marketing surveillance confirms that cough is not a characteristic adverse effect of sacubitril/valsartan 2, 6

Practical Clinical Application

When managing patients with heart failure:

  • If a patient develops troublesome cough on an ACE inhibitor (one that stops them from sleeping), European Society of Cardiology guidelines recommend substitution with an ARB 4
  • Sacubitril/valsartan is superior to switching to a plain ARB because it provides additional mortality and morbidity benefits beyond simple ARB therapy 7, 3
  • The cough must be proven to be ACE inhibitor-induced by demonstrating it recurs after withdrawal and rechallenge 4

Important Caveats

When evaluating cough in heart failure patients:

  • Cough is common in heart failure patients due to smoking-related lung disease and other comorbidities 4
  • Pulmonary edema must be excluded when new or worsening cough develops, as this is a symptom of decompensated heart failure 4
  • Not all ACE inhibitor-induced cough requires discontinuation—only troublesome cough that significantly impacts quality of life 4

Actual Side Effects of Sacubitril/Valsartan

The real adverse effects to monitor include:

  • Symptomatic hypotension (most common, more frequent than with ACE inhibitors) 7, 1
  • Hyperkalemia (less common than with ACE inhibitors but still requires monitoring) 1, 2
  • Worsening renal function (requires serial monitoring of creatinine and eGFR) 1, 6
  • Angioedema (rare but serious; higher risk in Black patients and those with prior angioedema) 1, 5

References

Research

The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review.

Journal of cardiovascular pharmacology and therapeutics, 2022

Research

Sacubitril/valsartan in heart failure: latest evidence and place in therapy.

Therapeutic advances in chronic disease, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2017

Guideline

Role of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.